Pharmacy Times

JULY 10, 2025

2 Guiding prescribers and patients through initiation of lumatperone, adjusting dosage amounts, and switching from other antipsychotics, emphasizing its favorable relapse reduction profile is key in preventing relapse.

Pharmacy Technician 20

Pharmacy Technician Hospitals Compounding Pharmacies Pharmacy Management 20

Pharmacy Times

JUNE 9, 2025

Abuse Deterrent Pharma, LLC (ADP), has licensed the LIMITX technology from Acura Pharmaceuticals for a number of pharmaceutical compounds. It has been used frequently for manufacturing poorly soluble compounds. trillion economic impact in 2020.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Compounding Pharmacy Management 29

Pharmacy Times

JUNE 17, 2025

A group of experts will present an encore abstract titled " Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using Real-World Data " at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20.

Dosage 26

Dosage Pharmacy Technician Compounding Pharmacies Inpatient 26

Pharmacy Times

JUNE 20, 2025

They have a team of highly skilled distribution professionals who can juggle efficacy and safety checks along with compounding as if they were conductors of a world-class symphony. We need people to coordinate and track prior authorizations, write persuasive appeal letters, and keep patients updated.

Pharmacy Technician 46

Pharmacy Technician Compounding Compounding Pharmacies Biosimilars 46

Pharmacy Times

JUNE 10, 2025

1 "[Meloxicam injection] demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," Ron Scarboro, chief executive officer at Azurity Pharmaceuticals, said in a press release. December 21, 2004. Subscribe Now!

Pharmacy Technician 29

Pharmacy Technician HIV Treatment and Prevention Agents Compounding Pharmacies Biosimilars 29

Pharmacy Times

JUNE 19, 2025

Development Trends: Oncology at the Forefront Gene therapy currently ranks third among therapeutic focus areas, with 2151 compounds in development in 2024 ( Figure ). 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. 6 CAR T-cell therapies continue to dominate the genetically modified space.

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Compounding Pharmacies 26

Pharmacy Times

JUNE 27, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician 20

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunity 20

Pharmacy Times

JULY 7, 2025

Limitations included open-label design and dosage constraints, but the multicountry approach enhanced generalizability and external validity. All patients underwent a 20-week correction period for dosage titration and Hb correction, which was followed by an 8-week evaluation for efficacy assessments. 1 REFERENCES 1.

Pharmacy Technician 39

Pharmacy Technician Compounding Pharmacies Dosage Diabetes 39

Pharmacy Times

JUNE 13, 2025

In addition, the dosage [of 2000 IU per day] used in the research is far below the target dose for correcting vitamin D deficiency, which is usually 50,000 IU per week,” Carvalho-Pessoa said in a news release. 1,2 “Even with a small sample of participants, it was possible to observe a significant difference in the response to chemotherapy.

Chemotherapy 56

Chemotherapy Pharmacy Technician Immunity Immunization 56

Pharmacy Times

JUNE 20, 2025

Selection of an appropriate OTC analgesic should take into consideration various patient factors, including the patient’s overall health status, current medical conditions, and medication profile, as well as patient preferences, which are often influenced by dosage form, required dosing intervals, and cost of OTC medication.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Hospitals Pharmacy Management 26

Pharmacy Times

JUNE 16, 2025

The biosimilar demonstrated comparable efficacy and safety to Stelara in a phase 3 clinical trial, supporting its FDA approval. Steqeyma provides a new dosage form and strength, enhancing treatment flexibility for young patients with chronic inflammatory conditions. The biosimilar is a 45 mg/0.5

Biosimilars 41

Biosimilars Pharmacy Technician Compounding Pharmacies Immunity 41

Pharmacy Times

JUNE 30, 2025

2,3 LIMBER is a phase 1, open-label, dose escalation study evaluating INCB057643 as a monotherapy at a dose escalation of 4 to 12 mg daily (part 1) or in combination with ruxolitinib at a dosage of 4 mg once daily and escalating to the maximum tolerated dose in part 1 (part 2). Subscribe Now!

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Compounding Pharmacy Management 26

Pharmacy Times

JUNE 16, 2025

The investigators assessed a total of 90 patients who received talquetamab at a dosage of 0.8 mg/kg once every 2 weeks plus teclistamab at a dosage of 3.0 2 As a combination therapy, talquetamab and teclistamab show significant promise in the phase 1b/2 dose escalation and expansion in the RedirecTT-1 trial (NCT04586426).

Pharmacy Technician 20

Pharmacy Technician Compounding Pharmacies Immunity Immunization 20

Pharmacy Times

JUNE 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Dosage Pharmacy Management 29

PharmaTech

JUNE 24, 2025

billion by 2034, exhibiting a compound average growth rate of 1.2% Recent Videos Related Content Six Biosimilars Part of EMA’s Authorization Recommendations in June Susan Haigney June 23rd 2025 Article A total of 13 drugs were granted recommendation for market authorization at EMA’s CHMP June 2025 meeting. during 2025–2034 (26).

Vaccines 59

Vaccines Dosage Drug Development Immunity 59

Pharmacy Times

JUNE 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Dosage Pharmacy Management 29

PharmaTech

JUNE 20, 2025

BI’s OpnME platform access aims to enhance Abu Dhabi’s clinical research by providing compounds, networks, and collaboration tools. Abbott’s pact focuses on localizing pharma manufacturing, biosimilar development, and advancing UAE’s digital health initiatives.

Dosage 59

Dosage Drug Development Vaccines Packaging 59

FDA Law Blog: Biosimilars

AUGUST 14, 2023

These figures confirm that, although the vast percentage of active ingredients of important pharmaceuticals comes from overseas, the actual manufacturing of finished dosage form drugs occurs in the United States or Europe (broadly defined to include the UK).

Dosage 52

Dosage Compounding 52

PharmaShots

JUNE 28, 2023

Consistent with prior periods, Enbrel continued to lose market share, and this decline was compounded by a reduction in the growth rate of the rheumatology market as a result of COVID-19. Some of its approved biosimilars are mentioned below along with the regulatory bodies they are approved by*. This list is not an exhaustive list.

Biosimilars 40

Biosimilars Insurance Coverage and Processing Dosage Compounding 40

Pharma in Brief

JANUARY 25, 2023

Combination use : The FC found that a generic manufacturer’s single-compound product would induce infringement of claims to a combination therapy (see here ). Such cases typically concern “skinny labels” in which the generic seeks to avoid reference to indications related to the patented use.

Biosimilars 52

Biosimilars Dosage Labelling Compounding 52

FDA Law Blog: Biosimilars

JANUARY 18, 2024

whether growing or not; its seeds; resin extracted from any part; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin. Thirty-eight states currently authorize marijuana in different dosage formulations for specific qualifying medical conditions. 21 U.S.C. § 802(16)(A).

Controlled Substances 69

Controlled Substances Chemotherapy Compounding Dosage 69